Nucleai vs Valar Labs (2026)
Both extract predictions from tissue, for different buyers. Nucleai serves drug developers: it applies computer vision and machine learning to H&E, immunohistochemistry, multiplex imaging and spatial transcriptomics, links tissue features to clinical outcomes, and delivers the work as expert led analysis for translational and biomarker teams, including an ongoing collaboration with Gilead on its ADC clinical programs. Valar Labs serves clinicians. Its Vesta tests predict treatment response and prognosis from routine H&E slides and are performed in its own CLIA certified laboratory, starting in non muscle invasive bladder cancer, with tests for advanced prostate and pancreatic cancer also offered. Vesta Bladder Risk Stratify Dx received FDA Breakthrough Device Designation in May 2026. Nucleai is a research partner for trials; Valar is a test a clinician orders for a patient.
- Analysis across H&E, immunohistochemistry, multiplex imaging and spatial transcriptomics, linked to clinical outcomes.
- Expert led delivery for biopharma translational and biomarker teams, across more than 12 clinical trials and 30 indications.
- An ongoing collaboration with Gilead on its ADC clinical programs.
- Predictions from the routine H&E slide a laboratory already produces, with no new assay.
- Tests run in its own CLIA certified, CAP accredited laboratory and ordered per test.
- Two bladder cancer tests, with Breakthrough Device Designation for Vesta Bladder Risk Stratify Dx in May 2026.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Nucleai and Valar Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Nucleai | Valar Labs |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2016 | 2021 |
| Headquarters | Tel Aviv, Israel | Palo Alto, California, United States |
| Website | nucleai.ai | valarlabs.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Valar Labs
-
Model / architecture
Valar Labs described CHAI, the vision foundation model behind its tests, in the first of a four part series.
Source -
Clinical evidence
Valar Labs and clinical partners published a peer-reviewed study in Urologic Oncology detailing the development and validation of an image-only AI prognostic biomarker for muscle-invasive bladder cancer (MIBC).
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Tissue intelligence company for drug development, applying computer vision and machine learning to H&E, immunohistochemistry, multiplex imaging and spatial transcriptomics and linking tissue features to clinical outcomes. Delivered as expert led analysis for biopharma translational, biomarker and translational pathology teams, including an ongoing collaboration with Gilead on its ADC clinical programs, with work across more than 12 clinical trials and 30 indications.
Source: AI Health Index, September 2026
Valar Labs is a precision oncology company, founded in 2021, whose tests predict treatment response and prognosis from routine H and E slides using its Computational Histology AI platform, trained on more than 500,000 pathologist annotations. The tests run in Valar's own CLIA certified laboratory and are ordered by physicians through a web portal, with results in two to three days.
Source: AI Health Index, September 2026
Questions buyers ask
How do Nucleai and Valar Labs work with the EHR?
For Nucleai, the company has partnered with a digital pathology platform vendor to embed its biomarker technology in that vendor's software, works with spatial biology instrument platforms, and links tissue findings with clinical outcomes data supplied by sponsors.
The clinic submits basic patient information through Valar's secure online portal, Valar requests the specimen from pathology, and results come back in about two to three days for prostate and pancreas and about three days for bladder. A clinician quoted on the bladder page describes fitting it into the practice's workflow. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Nucleai and Valar Labs priced and sold?
In Nucleai's case, the commercial model appears to combine pharmaceutical partnership agreements with platform access, and neither structure nor economics are disclosed.
Valar runs a Financial Access Program for patients with financial need. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Nucleai and Valar Labs handle patient data?
The user terms (31 March 2026) say Nucleai may use users' input and content to further develop, improve and enhance the solution, including through machine learning, subject to any customer services agreement.
The Notice of Privacy Practices (effective 1 January 2025) lets Valar de-identify health information and use it for research with the protections the law requires, and requires written authorization for marketing and any sale. The website privacy policy (29 April 2024) says personal information may be used for research and development, including to create de-identified data. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Nucleai and Valar Labs cover?
For Nucleai, clinical diagnostic use is not the current scope, and the user terms state the solution is not intended to diagnose or treat.
With Valar Labs, all run on existing H and E slides. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Neither is a cleared device: Nucleai's terms say its solution is not intended to diagnose or treat, and Valar's tests are laboratory developed, with a Breakthrough designation rather than a clearance.
Ask both which validation cohorts stand behind the figures they quote, and how the patient data used to build their models was governed.